GLAXOSMITHKLINE PLC Form 6-K October 07, 2013

FORM 6-K

## SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending October 2013

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

\_

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary Shares of GlaxoSmithKline plc in respect of the under-mentioned persons, arising from the purchase of Ordinary Shares on 4 October 2013 at a price of 1558.50 pence per Ordinary Share following the re-investment of dividends on shares held within an ISA:

Director/PDMR	Number of Shares	Connected Person	Number of Shares
	0	Lady C Witty	7
Witty Mr S M Bicknell	93	-	-
Mr D S Redfern	-18	-	-
Mrs V A Whyte 1	5	-	-

The Company and the above-mentioned persons were advised of this information on 7 October 2013.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).

S M Bicknell Company Secretary

7 October 2013

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

(Registrant)

Date: October 07, 2013

By: SIMON BICKNELL

Simon Bicknell Authorised Signatory for and on behalf of GlaxoSmithKline plc